IR plays a critical role in having a global impact on patient care. As the specialty grows, so does the demand for research and evidence.
In May 2020, in response to the global COVID-19 pandemic, SIR Foundation issued a request for letters of intent (LOIs) for emergency research funding to address a novel IR-based therapeutic approach to the care of COVID-19 patients using multidisciplinary, minimally invasive/locoregional therapies with collaborators outside of IR.
SIR Foundation announces COVID-19 grant recipient
SIR Foundation awarded the Emergency Funding for COVID-19 (EFC-19) research grant to Clifford R. Weiss, MD, FSIR, and Franco D’Alessio, MD, of Johns Hopkins University for their novel potential therapy to treat COVID-19. As part one of a double-blinded randomized trial, “Regulatory T-cell transfusion for lung injury due to COVID-19 pneumonia (RESOLVE),” this collaboration between IR and pulmonary and critical care medicine may help find a treatment for critically ill COVID-19 patients.
